Allergan Tops on Q3 Earnings, Revenues Shoot Up Y/Y
Allergan plc’s AGN third quarter 2015 earnings came in at $3.48 per share, well above the Zacks Consensus Estimate of $3.20 per share and 65% above the year-ago period. Revenues for the reported quarter came in at $4.089 billion, up 90% from the year-ago period, but just shy of the Zacks Consensus Estimate of $4.092 billion. Quarterly Details Allergan is treating its Global Generics business as discontinued operations from the third quarter following its agreement to divest the business to Teva Pharmaceutical Industries Ltd […]